117 related articles for article (PubMed ID: 24025538)
1. Personalizing therapy for colorectal cancer.
Wong A; Ma BB
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):139-44. PubMed ID: 24025538
[TBL] [Abstract][Full Text] [Related]
2. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer.
Sideris M; Papagrigoriadis S
Anticancer Res; 2014 May; 34(5):2061-8. PubMed ID: 24778007
[TBL] [Abstract][Full Text] [Related]
3. [Genetic and epigenetic changes in colorectal cancer and genetic testing for personalized medicine].
Suehiro Y; Hinoda Y
Rinsho Byori; 2012 Oct; 60(10):976-81. PubMed ID: 23323463
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
[TBL] [Abstract][Full Text] [Related]
5. Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine.
Shi C; Washington K
Am J Clin Pathol; 2012 Jun; 137(6):847-59. PubMed ID: 22586043
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer: how emerging molecular understanding affects treatment decisions.
Sridharan M; Hubbard JM; Grothey A
Oncology (Williston Park); 2014 Feb; 28(2):110-8. PubMed ID: 24701697
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
8. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
[TBL] [Abstract][Full Text] [Related]
9. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895
[TBL] [Abstract][Full Text] [Related]
10. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.
Kawakami K; Matsunoki A; Kaneko M; Saito K; Watanabe G; Minamoto T
Cancer Sci; 2011 Jan; 102(1):166-74. PubMed ID: 21087350
[TBL] [Abstract][Full Text] [Related]
11. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Jun; 38(6):842-9. PubMed ID: 17350669
[TBL] [Abstract][Full Text] [Related]
14. The role of tumor markers and biomarkers in colorectal cancer.
Lech G; Slotwinski R; Krasnodebski IW
Neoplasma; 2014; 61(1):1-8. PubMed ID: 24195503
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.
Mármol I; Sánchez-de-Diego C; Pradilla Dieste A; Cerrada E; Rodriguez Yoldi MJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106826
[TBL] [Abstract][Full Text] [Related]
17. Colorectal Cancer Biology, Diagnosis, and Therapeutic Approaches.
Dariya B; Aliya S; Merchant N; Alam A; Nagaraju GP
Crit Rev Oncog; 2020; 25(2):71-94. PubMed ID: 33389859
[TBL] [Abstract][Full Text] [Related]
18. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.
Deschoolmeester V; Baay M; Specenier P; Lardon F; Vermorken JB
Oncologist; 2010; 15(7):699-731. PubMed ID: 20584808
[TBL] [Abstract][Full Text] [Related]
19. Towards personalized medicine of colorectal cancer.
Aziz MA; Yousef Z; Saleh AM; Mohammad S; Al Knawy B
Crit Rev Oncol Hematol; 2017 Oct; 118():70-78. PubMed ID: 28917272
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches.
Li F; Lin Y; Li R; Shen X; Xiang M; Xiong G; Zhang K; Xia T; Guo J; Miao Z; Liao Y; Zhang X; Xie L
Front Pharmacol; 2023; 14():1165666. PubMed ID: 37927605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
